Abstract

This anti-aging agent contains, as an active ingredient, a compound represented by formula (I), a racemate thereof, or a salt thereof. (In formula (I), a carbon atom in a glycerol skeleton may have a substituent, an oxygen atom bound to R1is represented by *, and R1 is a compound that may have a substituent.)

IPC Classes  ?

• A61K 31/661 - Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

3-δ3-δ33 in which δ of the perovskite crystal is filled with an oxygen atom.

IPC Classes  ?

• H01B 1/06 - Conductors or conductive bodies characterised by the conductive materialsSelection of materials as conductors mainly consisting of other non-metallic substances
• C01G 19/00 - Compounds of tin
• C01G 23/00 - Compounds of titanium
• H01B 1/08 - Conductors or conductive bodies characterised by the conductive materialsSelection of materials as conductors mainly consisting of other non-metallic substances oxides
• H01M 8/12 - Fuel cells with solid electrolytes operating at high temperature, e.g. with stabilised ZrO2 electrolyte
• H01M 8/1246 - Fuel cells with solid electrolytes operating at high temperature, e.g. with stabilised ZrO2 electrolyte characterised by the process of manufacturing or by the material of the electrolyte the electrolyte consisting of oxides

Abstract

A probe has a base sequence that does not hybridize with a nucleic acid of a mammal under stringent conditions, and has a sequence including a base sequence set forth in any of SEQ ID NOs:1 to 673. A probe set includes two or more kinds of the probes, and the two or more kinds of the probes do not hybridize with each other under stringent conditions.

IPC Classes  ?

• C12Q 1/6841 - In situ hybridisation

Abstract

This manipulator is provided with: at least one flexible actuation body which includes a curved flexible part; a beam part which has one end connected to the flexible part; and a shaft part to which the other end of the beam part is connected. The flexible actuation body is configured to be operable in a non-sliding manner with respect to the beam part and the shaft part.

IPC Classes  ?

• B25J 15/08 - Gripping heads having finger members
• B25J 17/02 - Wrist joints
• A61B 34/30 - Surgical robots

Abstract

Provided is a steel pipe for high pressure hydrogen piping, for use in fuel cell vehicles, having a chemical composition consisting of, by mass %, 0.17 to 0.27% C, 0.05 to 0.40% Si, 0.30 to 2.00% Mn, 0.035% or less P, 0.035% or less S, 0 to 0.50% Cu, 0 to 1.0% Mo, 0 to 0.15% V, and a balance being Fe and impurities. The steel pipe has a metallographic structure composed of a mixed structure of bainite and ferrite in a middle part of the thickness of the steel pipe, a tensile strength in a hydrogen atmosphere of 500 MPa or more and 900 MPa or less, and a hardness in the middle part of the thickness of the steel pipe of 160 HV1 or more and 280 HV1 or less, and a defect on the inner surface of the steel pipe has a depth of 200 μm or less at a maximum.

IPC Classes  ?

• F16L 9/02 - Rigid pipes of metal
• C22C 38/02 - Ferrous alloys, e.g. steel alloys containing silicon
• C22C 38/04 - Ferrous alloys, e.g. steel alloys containing manganese
• C22C 38/06 - Ferrous alloys, e.g. steel alloys containing aluminium
• C22C 38/14 - Ferrous alloys, e.g. steel alloys containing titanium or zirconium
• C22C 38/16 - Ferrous alloys, e.g. steel alloys containing copper
• C22C 38/26 - Ferrous alloys, e.g. steel alloys containing chromium with niobium or tantalum

Abstract

By using this photon upconversion porous body which has a skeleton part that includes a donor and an acceptor, and a through hole of, for example, 0.1 µm to 100 µm, UC light irradiation in a flow system becomes possible in various fields including a photochemical reaction in which UC light is used.

IPC Classes  ?

• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• C08F 2/44 - Polymerisation in the presence of compounding ingredients, e.g. plasticisers, dyestuffs, fillers
• C08L 101/00 - Compositions of unspecified macromolecular compounds
• G02B 5/20 - Filters

Abstract

A medicament and method for treating circulatory diseases accompanied by inflammation of a cardiovascular system related to IL-6 and/or IL-1β and a medicament and method for treating circulatory diseases accompanied by inflammation of a cardiovascular system related to IL-6 and/or IL-1β. The method involves administering a medicament including an IL-6 and/or IL-1β suppressor including a compound represented by the following formula (I) A medicament and method for treating circulatory diseases accompanied by inflammation of a cardiovascular system related to IL-6 and/or IL-1β and a medicament and method for treating circulatory diseases accompanied by inflammation of a cardiovascular system related to IL-6 and/or IL-1β. The method involves administering a medicament including an IL-6 and/or IL-1β suppressor including a compound represented by the following formula (I) A medicament and method for treating circulatory diseases accompanied by inflammation of a cardiovascular system related to IL-6 and/or IL-1β and a medicament and method for treating circulatory diseases accompanied by inflammation of a cardiovascular system related to IL-6 and/or IL-1β. The method involves administering a medicament including an IL-6 and/or IL-1β suppressor including a compound represented by the following formula (I) where R1 and R2 are each independently a hydrogen atom or a methyl group, or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 9/12 - Antihypertensives

Abstract

This method for producing a deuterated compound involves reacting an amide or an ester with a deuterium source in the presence of a base and a Lewis acid selected from a metal triflate and a metal triflyl imide, and thereby deuterating the α-hydrogen of the amide or ester.

IPC Classes  ?

• C07C 231/12 - Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
• C07B 59/00 - Introduction of isotopes of elements into organic compounds
• C07C 67/30 - Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
• C07C 69/734 - Ethers
• C07C 235/34 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
• C07C 235/38 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
• C07D 207/27 - 2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
• C07D 209/16 - Tryptamines
• C07D 209/28 - 1-(4-Chlorobenzoyl)-2-methyl- indolyl-3-acetic acid, substituted in position 5 by an oxygen or nitrogen atomEsters thereof
• C07D 209/44 - Iso-indolesHydrogenated iso-indoles
• C07D 209/48 - Iso-indolesHydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
• C07D 215/20 - Oxygen atoms
• C07D 215/227 - Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
• C07D 279/06 - 1,3-ThiazinesHydrogenated 1,3-thiazines not condensed with other rings
• C07D 295/185 - Radicals derived from carboxylic acids from aliphatic carboxylic acids
• C07D 307/81 - Radicals substituted by nitrogen atoms not forming part of a nitro radical
• C07D 311/20 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 hydrogenated in the hetero ring
• C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 471/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups in which the condensed systems contains four or more hetero rings
• C07D 491/22 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or in which the condensed system contains four or more hetero rings

Abstract

Methods are disclosed for inhibiting a liver disease in a subject. These methods include administering to the subject an effective amount of a phosphodiesterase (PDE) III inhibitor or 10,12-tricosadiynoic acid (TDYA), or a pharmaceutically acceptable salt thereof, thereby treating or preventing the liver disease in the subject. Also disclosed are compositions including an effective amount of a phosphodiesterase (PDE) III inhibitor or 10,12-tricosadiynoic acid (TDYA), or a pharmaceutically acceptable salt thereof, for use in inhibiting liver disease in a subject.

IPC Classes  ?

• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

A muscle enhancing agent according to the present invention contains a plasmalogen as an active ingredient.

IPC Classes  ?

• A61K 31/683 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
• A61K 35/57 - BirdsMaterials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
• A61K 35/618 - Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
• A61K 35/655 - Aquatic animals other than those covered by groups
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

A method in which carbon dioxide can be efficiently fixed, calcium carbonate that is a valuable can be efficiently produced from carbon dioxide, and a waste gypsum board can be effectively recycled without being wasted as it is by using the waste gypsum board for fixing carbon dioxide. This method includes: bringing a first solution containing an alkali metal hydroxide and gas containing carbon dioxide into contact with each other to produce a second solution containing an alkali metal salt; and bringing the second solution and a gypsum-containing material into contact with each other to produce calcium carbonate.

IPC Classes  ?

• B01D 53/62 - Carbon oxides
• B01D 53/14 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by absorption
• B01D 53/78 - Liquid phase processes with gas-liquid contact
• C01F 11/18 - Carbonates

Abstract

Provided is an electrode material which can achieve both high activity and potential cycle durability and from which a fuel cell electrode having, in particular, excellent load fluctuation cycle characteristics is formed. This electrode material contains a conductive carrier and a catalyst composite supported on the conductive carrier, wherein the catalyst composite includes a PtTaCo composite composed of platinum (Pt) as a first component, tantalum (Ta) as a second component, and cobalt (Co) as a third component. A catalyst composite obtained after phase-separating the PtTaCo composite in the electrode material contains Pt-rich particles and Ta-rich particles.　

IPC Classes  ?

• H01M 4/90 - Selection of catalytic material
• B01J 23/89 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of the iron group metals or copper combined with noble metals
• H01M 4/86 - Inert electrodes with catalytic activity, e.g. for fuel cells
• H01M 4/92 - Metals of platinum group
• H01M 8/10 - Fuel cells with solid electrolytes

Abstract

The present invention provides a method for culturing a fish germ stem cell, including culturing the stem cell on a surface coated with vitronectin and in a medium containing the following 8 components: (1) insulin, (2) selenium, (3) transferrin, (4) L-ascorbic acid, (5) FGF2, (6) TGFβ, (7) NaHCO3 or KHCO3, (8) L-glutamine.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor

Abstract

A method for assisting in diagnosis of mental stress according to the present invention comprises: a step for measuring the concentrations of a plurality of components contained in a biological sample collected from a subject; a step for classifying the subject on the basis of personality characteristics; and a step for generating stress diagnosis assistance information, which is information for diagnosing the degree of mental stress of the subject, on the basis of the measured concentrations of the components and the classification based on personality characteristics. The plurality of components include betaine, creatine, GABA, creatinine, serotonin, kynurenic acid, 3-hydroxybutyric acid, and citric acid. According to the aforementioned method, it is possible to provide information serving as an aid for accurately diagnosing the presence and degree of mental stress in a subject.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/70 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving creatine or creatinine
• G06N 20/00 - Machine learning

Abstract

Provided is a medical device containing a polyurethane resin elastomer that can achieve both biocompatibility and physical properties. The medical device in an embodiment contains a polyurethane resin elastomer and water contained in the polyurethane resin elastomer. The polyurethane resin elastomer contains polyethylene glycol and a polyisocyanate as constituents, the polyethylene glycol has a number average molecular weight of 200 or more and 2200 or less, and the polyethylene glycol is present in an amount of 1 mass % or higher and lower than 50 mass % based on 100 mass % of the constituents of the polyurethane resin elastomer.

IPC Classes  ?

• A61L 31/06 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• A61L 31/10 - Macromolecular materials
• A61L 31/14 - Materials characterised by their function or physical properties
• C08L 75/04 - Polyurethanes

Abstract

A compound represented by formula (I), its racemic form, or their salt, wherein X represents an oxygen atom, a nitrogen atom or a sulfur atom; R1 represents an unsaturated aliphatic hydrocarbon group; R2 represents a saturated or unsaturated aliphatic hydrocarbon group; and R3 represents choline, ethanolamine, inositol or serine. A compound represented by formula (I), its racemic form, or their salt, wherein X represents an oxygen atom, a nitrogen atom or a sulfur atom; R1 represents an unsaturated aliphatic hydrocarbon group; R2 represents a saturated or unsaturated aliphatic hydrocarbon group; and R3 represents choline, ethanolamine, inositol or serine.

IPC Classes  ?

• C07F 9/10 - Phosphatides, e.g. lecithin
• A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

a b1cd3-δ3-δ. A represents a group 3 element. B represents a group 2 element. C represents an element selected from among group 8 elements and group 9 elements. D represents an element selected from among a platinum group element and gold. a represents a number of 0.10-1.10. b represents a number of 0-0.90. c represents a number of 0.40-1.10. d represents a number of 0.15-0.40. The value of a+b is 0.80-1.20. The value of c+d is 0.80-1.20.

IPC Classes  ?

• C01G 55/00 - Compounds of ruthenium, rhodium, palladium, osmium, iridium, or platinum
• H01B 1/06 - Conductors or conductive bodies characterised by the conductive materialsSelection of materials as conductors mainly consisting of other non-metallic substances
• H01M 4/86 - Inert electrodes with catalytic activity, e.g. for fuel cells
• H01M 8/12 - Fuel cells with solid electrolytes operating at high temperature, e.g. with stabilised ZrO2 electrolyte
• H01M 8/1246 - Fuel cells with solid electrolytes operating at high temperature, e.g. with stabilised ZrO2 electrolyte characterised by the process of manufacturing or by the material of the electrolyte the electrolyte consisting of oxides

Abstract

This ocular drug comprises: a first aqueous phase 10; a gelled oil phase 20 in which the first aqueous phase 10 is dispersed; a second aqueous phase 30 in which the oil phase 20 is dispersed; and an eye disease therapeutic agent disposed in the first aqueous phase 10.

IPC Classes  ?

• A61K 9/113 - Multiple emulsions, e.g. oil-in-water-in-oil
• A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
• A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
• A61P 27/02 - Ophthalmic agents

Abstract

The present invention provides either electrode material (A) or electrode material (B). An electrode material being an electrode material (A) including a porous composite support including, a carbon support formed of mesoporous carbon having an internal surface inside pores and an external surface outside the pores, and an electron conducting oxide adhered to at least the internal surface inside the pores of the mesoporous carbon, and electrode catalyst particles supported on the porous composite support, in which some or all of the electrode catalyst particles are supported via the electron conducting oxide in the pores of the mesoporous carbon; or an electrode material (B) including a carbon support formed of mesoporous carbon having an internal surface inside pores and an external surface outside the pores, and an electrode catalyst composite body adhered to at least the internal surface inside the pores of the mesoporous carbon, in which the electrode catalyst composite body includes electrode catalyst particles and an electron conducting oxide, and the electron conducting oxide fills gaps between the electrode catalyst particles.

IPC Classes  ?

• H01M 8/1048 - Ion-conducting additives, e.g. ion-conducting particles, heteropolyacids, metal phosphate or polybenzimidazole with phosphoric acid
• H01M 8/1004 - Fuel cells with solid electrolytes characterised by membrane-electrode assemblies [MEA]
• H01M 8/1067 - Polymeric electrolyte materials characterised by their physical properties, e.g. porosity, ionic conductivity or thickness
• H01M 8/12 - Fuel cells with solid electrolytes operating at high temperature, e.g. with stabilised ZrO2 electrolyte
• H01M 8/1246 - Fuel cells with solid electrolytes operating at high temperature, e.g. with stabilised ZrO2 electrolyte characterised by the process of manufacturing or by the material of the electrolyte the electrolyte consisting of oxides

Abstract

Provided is a method of producing a polymer-coated substrate for capturing cancer cells in which a polymer layer is stably maintained on the surface of the substrate for a long time even in a liquid environment. The method of producing a polymer-coated substrate for capturing cancer cells includes forming a polymer layer using a hydrophilic polymer represented by the following formula (I) on a surface of a substrate having undergone anti-reflection treatment, Provided is a method of producing a polymer-coated substrate for capturing cancer cells in which a polymer layer is stably maintained on the surface of the substrate for a long time even in a liquid environment. The method of producing a polymer-coated substrate for capturing cancer cells includes forming a polymer layer using a hydrophilic polymer represented by the following formula (I) on a surface of a substrate having undergone anti-reflection treatment, Provided is a method of producing a polymer-coated substrate for capturing cancer cells in which a polymer layer is stably maintained on the surface of the substrate for a long time even in a liquid environment. The method of producing a polymer-coated substrate for capturing cancer cells includes forming a polymer layer using a hydrophilic polymer represented by the following formula (I) on a surface of a substrate having undergone anti-reflection treatment, wherein R1 represents a hydrogen atom or a methyl group; R2 represents an alkyl group; m represents 1 to 5; and n represents the number of repetitions.

IPC Classes  ?

• C09D 133/14 - Homopolymers or copolymers of esters of esters containing halogen, nitrogen, sulfur or oxygen atoms in addition to the carboxy oxygen
• G01N 1/30 - StainingImpregnating

Abstract

Provided is a labeling method having a step of labeling a substrate having a carbon-hydrogen bond with an oxygen isotope by using a catalyst and an oxidant produced from a hypervalent iodine compound having an ester structure and labeled water labeled with at least one oxygen isotope selected from the group consisting of 17O and 18O. Also provided is an oxidant for labeling that is produced from a hypervalent iodine compound having an ester structure and labeled water labeled with at least one oxygen isotope selected from the group consisting of 17O and 18O and labels a substrate having a carbon-hydrogen bond with an oxygen isotope in the co-presence of a catalyst.

IPC Classes  ?

• C07B 59/00 - Introduction of isotopes of elements into organic compounds
• C07F 15/00 - Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table

Abstract

A machine learning device includes a processor that executes a procedure. The procedure includes: based on route information indicating movement conditions of a plurality of respective moving bodies in a specific geographical range at each of a plurality of time points, generating traffic flow information indicating a number of moving bodies located at respective route segments within the specific geographical range for each of the plurality of time points; and by using training data that includes the traffic flow information as input feature values and includes information indicating a degree of congestion of traffic in the specific geographical range at a time point corresponding to the traffic flow information as label information, training a machine learning model for deriving a degree of congestion of traffic corresponding to traffic flow information.

IPC Classes  ?

• G06N 3/08 - Learning methods
• G08G 1/01 - Detecting movement of traffic to be counted or controlled

Abstract

Circuitry that executes a procedure including: from route information indicating a movement condition of moving bodies in a first period for each of a plurality of time points, extracting route information of moving bodies that started to move in a second period that is contained in, and shorter than, the first period; generating tally information in which a number of the moving bodies is tallied for each combination of a departure point and an arrival point in movements of the moving body contained in the route information, and generating information indicating a degree of congestion of traffic in the specific geographical range; and generating training data, in which the tally information is employed as input feature values and the information indicating the degree of congestion is employed as label information, as training data for a machine learning model for deriving a degree of congestion of traffic corresponding to tally information.

IPC Classes  ?

• G01C 21/34 - Route searchingRoute guidance
• G06N 20/00 - Machine learning
• G08G 1/01 - Detecting movement of traffic to be counted or controlled

Abstract

The present invention provides a method for sorting plant seeds having a desired trait, the method including the following first to seventh steps: (First step) A step for extracting some seeds from a seed group. (Second step) A step for constructing a data set with respect to the extracted seeds, the step for constructing a data set including the following (a) to (c): (a) beaming light onto the extracted seeds and acquiring spectral data and/or spectral data derived therefrom; (b) subjecting the seeds for which spectral data has been acquired to quality inspection with respect to the desired trait, and determining the advance quality rate of the extracted seeds, the advance quality rate being defined by the following formula: [Advance quality rate (%)] = [number of seeds having desired trait from among seeds subjected to quality evaluation] / [number of seeds subjected to quality evaluation] × 100; (c) associating the spectral data for each seed and the result of the quality inspection. (Third step) A step for applying multivariate discriminant analysis to the data set constructed in the second step and thereby deriving candidates for a good/poor discrimination model for calculating a discrimination score for the desired trait in each seed. (Fourth step) A step for selecting a discrimination model from the candidates for a good/poor discrimination model derived in the third step, the step including selecting as a good/poor discrimination model a candidate that satisfies the criterion that the conformity rate exceeds the advance quality rate under a standard sorting condition, where the recovery rate and the conformity rate are defined by the following formulae, and a sorting condition that the advance quality rate and the recovery rate have the same value is defined as the "standard sorting condition": [Recovery rate (%)] = [Number of seeds selected on the basis of discrimination score from among seeds subjected to quality evaluation] / [number of seeds subjected to quality evaluation] × 100 [Conformity rate (%)] = [Number of seeds with desired trait from among seeds subjected to quality evaluation and selected on the basis of discrimination score] / [number of seeds selected on the basis of discrimination score from among seeds subjected to quality evaluation] × 100 (Fifth step) A step for beaming light onto the remaining seeds not extracted from the seed group in the first step and/or other seeds obtained under essentially the same conditions as those for said seeds and acquiring spectral data, and applying the discrimination model selected in the fourth step to the spectral data to determine the discrimination score for each seed. (Sixth step) A step for determining a threshold for the discrimination score on the basis of the discrimination scores determined in the fifth step. (Seventh step) A step for comparing the discrimination scores of the respective seeds determined in the fifth step with the threshold for the discrimination score determined in the sixth step, and thereby recovering seeds predicted to have the desired trait.

IPC Classes  ?

• G01N 21/3563 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light for analysing solidsPreparation of samples therefor

Abstract

Provided are: a novel enzyme composition having an efficient single-stranded DNA linking activity; and others. The present invention pertains to: a single-stranded DNA linking composition which is used for linking single-stranded DNA that serves as at least one acceptor to single-stranded DNA that serves as at least one donor, the composition containing (a) a protein comprising the amino acid sequence represented by SEQ ID NO:2 or SEQ ID NO:4 and/or (b) a protein comprising an amino acid sequence having 70% or higher identity with the amino acid sequence represented by SEQ ID NO:2 or SEQ ID NO:4 and having a single-stranded DNA linking activity; and others.

IPC Classes  ?

• C12N 9/00 - Enzymes, e.g. ligases (6.)ProenzymesCompositions thereofProcesses for preparing, activating, inhibiting, separating, or purifying enzymes
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/52 - Genes encoding for enzymes or proenzymes

Abstract

222 by bringing the starting material gas into contact with a cathode catalyst without bringing the starting material gas into contact with the cathode electrode.　(a) The cathode electrode structure is provided with: a porous structure that is provided so as to be in contact with a part of the first flow path; a cathode catalyst layer that is provided so as to be in contact with the porous structure; and a cathode electrode that is electrically connected to a catalyst of the cathode catalyst layer. (b) The cathode electrode structure is provided with a porous structure which is provided, in the surface thereof, with a cathode electrode and a cathode catalyst that is electrically connected to the cathode electrode, and which is provided so as to be in contact with a part of the first flow path. (c) The cathode electrode structure is provided with: a porous structure which is formed of a conductive catalyst metal that is electrically connected to a cathode electrode, and which is provided so as to be in contact with a part of the first flow path; and a cathode catalyst layer.

IPC Classes  ?

• C25B 3/26 - Reduction of carbon dioxide
• C25B 1/23 - Carbon monoxide or syngas
• C25B 3/03 - Acyclic or carbocyclic hydrocarbons
• C25B 3/07 - Oxygen containing compounds
• C25B 9/00 - Cells or assemblies of cellsConstructional parts of cellsAssemblies of constructional parts, e.g. electrode-diaphragm assembliesProcess-related cell features
• C25B 9/23 - Cells comprising dimensionally-stable non-movable electrodesAssemblies of constructional parts thereof with diaphragms comprising ion-exchange membranes in or on which electrode material is embedded

Abstract

A medical coating agent contains a polymer including a structural unit (A) derived from an ethylenically unsaturated monomer having a urethane bond. The polymer has a glass transition temperature of −25° C. or lower in a saturated hydration state, the state being defined as such a hydration state of the polymer that the top of the endothermic peak attributed to melting of ice emerges at 0° C. in a DSC curve obtained when the polymer which has been hydrated is heated by means of a differential scanning calorimeter (DSC) at a rate of 5° C./minute.

IPC Classes  ?

• A61L 29/14 - Materials characterised by their function or physical properties
• A61L 29/08 - Materials for coatings
• A61L 31/10 - Macromolecular materials
• A61L 31/14 - Materials characterised by their function or physical properties

Abstract

An insulated wire includes a wire conductor and an insulation covering that is made of a crosslinked polymer material and covers the outer periphery of the wire conductor, the crosslinked polymer material includes a metal ion and a silicone resin having a side chain which includes a substituent group capable of forming an ionic bond with the metal ion, and the silicone resin forms a crosslinked product through the ionic bond between the substituent group and the metal ion. A crosslinkable polymer composition including a metal compound from which the metal ion is released by heat and the silicone resin is disposed on an outer periphery of the wire conductor, and then the crosslinked product is formed from the crosslinkable polymer composition by heating to produce the insulation covering made of the crosslinked polymer material, and thus the insulated wire is produced.

IPC Classes  ?

• C08G 77/398 - Polysiloxanes modified by chemical after-treatment containing atoms other than carbon, hydrogen, oxygen or silicon containing boron or metal atoms
• C08K 3/36 - Silica
• H01B 3/46 - Insulators or insulating bodies characterised by the insulating materialsSelection of materials for their insulating or dielectric properties mainly consisting of organic substances plasticsInsulators or insulating bodies characterised by the insulating materialsSelection of materials for their insulating or dielectric properties mainly consisting of organic substances resinsInsulators or insulating bodies characterised by the insulating materialsSelection of materials for their insulating or dielectric properties mainly consisting of organic substances waxes silicones
• H01B 7/00 - Insulated conductors or cables characterised by their form
• H01B 13/06 - Insulating conductors or cables

Abstract

3a+2b+1c3a+2b+1cM1aaM2bbM3cα6-2α3a+2b+1c3a+2b+1cM1aaM2bbM3c66 In formulae (1) and (2), M1is selected from the group consisting of Y, Sc, Al, Ga, In, La, Ce, Pr, Nd, Pm, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb, Lu, and combinations thereof; M2is selected from the group consisting of Zr, Hf, Ti, Si, Ge, Sn, and combinations thereof; and M3 is selected from the group consisting of Nb, Ta, V, P, Sb, Bi, and combinations thereof. Ch is selected from the group consisting of O, S, Se, Te and combinations thereof, and X is selected from the group consisting of F, Cl, Br, I, and combinations thereof.

IPC Classes  ?

• H01B 1/06 - Conductors or conductive bodies characterised by the conductive materialsSelection of materials as conductors mainly consisting of other non-metallic substances
• H01M 10/0562 - Solid materials

Abstract

The present invention provides a trisulfide-compound-containing agent for inhibiting nitration of tyrosine residues in hepatocyte growth factor, the trisulfide compound being: glutathione trisulfide or a pharmaceutically acceptable salt thereof; or a compound represented by formula (1) (wherein X represents —OR1 or —NR2R3, R1 represents a hydrogen atom or an alkyl group containing 1 to 6 carbon atoms, R2 and R3 independently represent a hydrogen atom or an alkyl group containing 1 to 6 carbon atoms, and the alkyl group may have one or more substituents selected from the group consisting of amino groups and carboxy groups), a pharmaceutically acceptable salt thereof, or a cyclodextrin clathrate thereof. The present invention provides a trisulfide-compound-containing agent for inhibiting nitration of tyrosine residues in hepatocyte growth factor, the trisulfide compound being: glutathione trisulfide or a pharmaceutically acceptable salt thereof; or a compound represented by formula (1) (wherein X represents —OR1 or —NR2R3, R1 represents a hydrogen atom or an alkyl group containing 1 to 6 carbon atoms, R2 and R3 independently represent a hydrogen atom or an alkyl group containing 1 to 6 carbon atoms, and the alkyl group may have one or more substituents selected from the group consisting of amino groups and carboxy groups), a pharmaceutically acceptable salt thereof, or a cyclodextrin clathrate thereof.

IPC Classes  ?

• A61K 31/385 - Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
• A61K 38/06 - Tripeptides
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit

Abstract

Provided is a method for producing a highly homogeneous antibody substrate conjugate, the method being capable of controlling the drug-antibody binding ratio and the modification position on an antibody. This method uses an enzyme conjugate capable of improving antibody modification efficiency and controlling the antibody modification site. This enzyme conjugate was developed using an active microorganism-derived transglutaminase precursor.　Provided is a microorganism-derived transglutaminase fusion product obtained by fusion of an active microorganism-derived transglutaminase precursor and an antibody-binding protein.

IPC Classes  ?

• C07K 19/00 - Hybrid peptides
• C07K 14/31 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
• C07K 14/315 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
• C12N 9/10 - Transferases (2.)
• C12N 15/13 - Immunoglobulins
• C12N 15/54 - Transferases (2)
• C12N 15/62 - DNA sequences coding for fusion proteins

Abstract

A pipette device according to the present disclosure comprises: a tubular pipe part that sucks in and dispenses an object via a working fluid; a driving part that drives a movable moving part; and an attachment part having detachably attached thereto a pump part in which the working fluid is retained and which sucks in the working fluid from the pipe part and discharges the working fluid to the pipe part in association with the movement of the moving part. The suction amount or the discharge amount of the working fluid corresponding to a prescribed amount of the movement of the moving part is different between when a first pump part is attached as the pump part to the attachment part and when a second pump part is attached as the pump part to the attachment part.

IPC Classes  ?

• B01L 3/02 - BurettesPipettes
• F04B 43/04 - Pumps having electric drive
• G01N 1/00 - SamplingPreparing specimens for investigation

Abstract

222 separation composite membrane, the method comprising: a step for forming a first separation layer including a polysiloxane-containing layer; and a step for forming a second separation layer selected from the group consisting of a polyethylene glycol-containing layer and an imidazolium salt-type ionic liquid component-containing layer on the first separation layer. In the step for forming the second separation layer, a polyethylene glycol-containing layer or an imidazolium salt-type ionic liquid component-containing layer is chemically bonded to the polysiloxane-containing layer to form the second separation layer.

IPC Classes  ?

• B01D 69/00 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or propertiesManufacturing processes specially adapted therefor
• B01D 69/12 - Composite membranesUltra-thin membranes
• B01D 71/06 - Organic material
• B01D 71/52 - Polyethers
• B01D 71/70 - Polymers having silicon in the main chain, with or without sulfur, nitrogen, oxygen or carbon only
• C08L 83/05 - Polysiloxanes containing silicon bound to hydrogen
• C08L 83/07 - Polysiloxanes containing silicon bound to unsaturated aliphatic groups

Abstract

The present invention provides a delayed fluorescent material which imparts element characteristics including improved roll-off characteristics and service life. Disclosed is an organic compound which is represented by formula (1-1) or (1-2). In formulae (1-1) and (1-2), Ra1to Ra4are each independently selected from among a hydrogen atom, an alkyl group, and the like. However, Ra1is not a hydrogen atom. X is a selenium atom or a tellurium atom. Y is selected from among an oxygen atom and the like. D1is a group represented by any one of formulae (2-1) to (2-5), and D2is a hydrogen atom or a group represented by any one of formulae (2-1) to (2-5). In formulae (2-1) to (2-5), * denotes a bonding position. Rb1to Rb9 are independently selected from among a deuterium atom, an alkyl group, and the like. Z is selected from among an oxygen atom and the like. E is a carbon atom, a silicon atom, or a germanium atom. l, m, n, r, and s are each an integer of 0 to 4 inclusive, o is an integer of 1 to 4 inclusive, p and q are each an integer of 0 or 1, and t and u are each an integer of 0 to 5 inclusive.

IPC Classes  ?

• C07F 5/02 - Boron compounds
• C09D 11/00 - Inks
• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• H10K 50/12 - OLEDs or polymer light-emitting diodes [PLED] characterised by the electroluminescent [EL] layers comprising dopants
• H10K 50/854 - Arrangements for extracting light from the devices comprising scattering means
• H10K 59/00 - Integrated devices, or assemblies of multiple devices, comprising at least one organic light-emitting element covered by group
• H10K 59/10 - OLED displays
• H10K 59/123 - Connection of the pixel electrodes to the thin film transistors [TFT]
• H10K 59/65 - OLEDs integrated with inorganic image sensors
• H10K 59/90 - Assemblies of multiple devices comprising at least one organic light-emitting element
• H10K 59/95 - Assemblies of multiple devices comprising at least one organic light-emitting element wherein all light-emitting elements are organic, e.g. assembled OLED displays
• H10K 71/12 - Deposition of organic active material using liquid deposition, e.g. spin coating
• H10K 85/30 - Coordination compounds
• H10K 85/60 - Organic compounds having low molecular weight
• H10K 101/20 - Delayed fluorescence emission
• H10K 101/40 - Interrelation of parameters between multiple constituent active layers or sublayers, e.g. HOMO values in adjacent layers

Abstract

An osteoarthritis progression inhibitor contains, as active substances, a G protein-coupled receptor kinase 5 inhibitor, and hyaluronic acid or a pharmaceutically acceptable salt thereof. The G protein-coupled receptor kinase 5 inhibitor may be Amlexanox. The osteoarthritis progression inhibitor may be administered by intraarticular injection. An osteoarthritis progression inhibition kit contains a G protein-coupled receptor kinase 5 inhibitor, and hyaluronic acid or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• A61K 31/728 - Hyaluronic acid
• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Abstract

An organic electroluminescent device having an anode, a cathode, and a light-emitting layer between the anode and the cathode, wherein the light-emitting layer contains at least a first organic compound, a second organic compound and a third organic compound satisfying the following formula (A), the second organic compound is a delayed fluorescent material, and the third organic compound is a light-emitting material, has a high light emission efficiency. Formula (A): ES1(A)>ES1(B)>ES1(C) wherein ES1(A), ES1(B) and ES1(C) each represent a lowest excited singlet energy level of the first organic compound, the second organic compound and the third organic compound, respectively.

IPC Classes  ?

• H10K 85/60 - Organic compounds having low molecular weight
• C07D 209/86 - CarbazolesHydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• H10K 50/11 - OLEDs or polymer light-emitting diodes [PLED] characterised by the electroluminescent [EL] layers
• H10K 101/00 - Properties of the organic materials covered by group
• H10K 101/10 - Triplet emission

Abstract

Provided is a calcium carbonate generation method and system in which calcium carbonate having a high purity can be generated using a calcium-containing waste. Provided is a calcium carbonate generation method of generating calcium carbonate from a calcium-containing waste, the calcium carbonate generation method including: a calcium dissolution step of adding aqueous hydrochloric acid to a calcium-containing waste and dissolving calcium to generate an aqueous solution containing a calcium ion; a separation step of adjusting a hydrogen ion concentration index of the aqueous solution containing a calcium ion and separating a component containing at least one selected from the group consisting of Si, Al, Mg, and heavy metal from the aqueous solution; and a calcium carbonate collection step of generating calcium carbonate using an aqueous solution obtained in the separation step and an aqueous solution containing potassium carbonate and/or sodium carbonate.

IPC Classes  ?

• C01F 11/18 - Carbonates
• B09B 3/70 - Chemical treatment, e.g. pH adjustment or oxidation
• B09B 101/45 - Concrete
• C01B 7/07 - Purification
• C01D 1/38 - PurificationSeparation by dialysis
• C01D 1/40 - PurificationSeparation by electrolysis
• C01D 7/07 - Preparation from the hydroxides

Abstract

Provided are a method for producing a functional sheet, an apparatus for producing a functional sheet, a system for producing a functional sheet, and a functional sheet that make it possible to appropriately align fine particles in a resin. A method for producing a functional sheet includes: a sheet formation step (ST2) for forming a sheet-like liquid resin containing a plurality of fine particles in at least a portion thereof; a rotation application step (ST21) for rotating the sheet-like liquid resin so that the sheet surface thereof is vertically inverted, while applying an electric field or a magnetic field in the thickness direction to the sheet-like liquid resin; and a curing step (ST22) for curing the sheet-like liquid resin.

IPC Classes  ?

• B29C 41/04 - Rotational or centrifugal casting, i.e. coating the inside of a mould by rotating the mould
• B29C 39/24 - Feeding the material into the mould
• B29C 39/44 - Measuring, controlling or regulating
• B29C 41/50 - Shaping under special conditions, e.g. vacuum
• C08K 3/013 - Fillers, pigments or reinforcing additives
• C08L 101/00 - Compositions of unspecified macromolecular compounds

Abstract

Provided are: a photodetection element comprising a substrate (101), a graphene layer (102) provided on the substrate (101), electrodes (103, 104) for reading an electric current or a voltage, the electrodes being electrically connected to the graphene layer (102), and a photoelectric conversion layer (105) electrically connected to the graphene layer (102), wherein the photoelectric conversion layer (105) comprises aggregates of semiconductor quantum dots and a ligand coordinated to the semiconductor quantum dots, and the ligand includes at least one compound selected from among thiocyanide compounds, dithiothreitol, and dithioerythritol; and a method for manufacturing the photodetection element. Also provided is an image sensor including the photodetection element.

IPC Classes  ?

• H01L 31/10 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof in which radiation controls flow of current through the device, e.g. photoresistors characterised by at least one potential-jump barrier or surface barrier, e.g. phototransistors
• H01L 27/146 - Imager structures

Abstract

A a crosslinkable polymer composition which provides a crosslinked product capable of both heat resistance and re-formability, a crosslinked polymer material capable of both heat resistance and re-formability, and an insulated wire and a wiring harness including the crosslinked polymer material. The crosslinkable polymer composition includes: ingredient A from which metal ion is released by heat; and ingredient B including an organic polymer having a side chain, including an electron-withdrawing substituent group capable of forming an ionic bond with the metal ion, and when B is crosslinked via the metal ion to form a crosslinked product, the product has a flow starting temperature of 190° C. or higher and 300° C. or lower. The crosslinked polymer material includes the crosslinked product of the crosslinkable polymer composition. The insulated wire includes a wire conductor, and an insulation coating including the crosslinked polymer material, and the wiring harness including the insulated wire.

IPC Classes  ?

• C08F 8/42 - Introducing metal atoms or metal-containing groups
• H01B 3/44 - Insulators or insulating bodies characterised by the insulating materialsSelection of materials for their insulating or dielectric properties mainly consisting of organic substances plasticsInsulators or insulating bodies characterised by the insulating materialsSelection of materials for their insulating or dielectric properties mainly consisting of organic substances resinsInsulators or insulating bodies characterised by the insulating materialsSelection of materials for their insulating or dielectric properties mainly consisting of organic substances waxes vinyl resinsInsulators or insulating bodies characterised by the insulating materialsSelection of materials for their insulating or dielectric properties mainly consisting of organic substances plasticsInsulators or insulating bodies characterised by the insulating materialsSelection of materials for their insulating or dielectric properties mainly consisting of organic substances resinsInsulators or insulating bodies characterised by the insulating materialsSelection of materials for their insulating or dielectric properties mainly consisting of organic substances waxes acrylic resins
• H01B 7/00 - Insulated conductors or cables characterised by their form
• H01B 7/08 - Flat or ribbon cables

Abstract

Provided is a light detecting element having: a substrate (101); a graphene layer (102) provided on the substrate (101); electrodes (103, 104) which are electrically connected to the graphene layer (102) and read current or voltage; and a photoelectric conversion layer (105) electrically connected to the graphene layer (102), wherein the photoelectric conversion layer (105) has an aggregate of semiconductor quantum dots and a ligand coordinated to the semiconductor quantum dots. The semiconductor quantum dots include group III-V semiconductor quantum dots. The ligand includes at least one selected from among an inorganic halide, a compound represented by formula (A), a compound represented by formula (B), and a compound represented by formula (C). Also provided are a method for manufacturing the light detecting element, and an image sensor including aforementioned light detecting element.

IPC Classes  ?

• H01L 31/10 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof in which radiation controls flow of current through the device, e.g. photoresistors characterised by at least one potential-jump barrier or surface barrier, e.g. phototransistors
• H01L 27/146 - Imager structures

Abstract

This method for producing a lignin decomposition product includes: a mixing step in which a mixture comprising a lignin-containing substrate and a catalyst containing at least one metal ion selected from the group consisting of divalent and trivalent metal ions is obtained; and a decomposition step in which the mixture is irradiated with visible light to decompose the lignin and obtain a lignin decomposition product. This method for producing methanol includes a step in which a mixture comprising a lignin-containing substrate and a catalyst containing at least one metal ion selected from the group consisting of divalent and trivalent metal ions is irradiated with visible light, thereby yielding methanol.

IPC Classes  ?

• C07C 29/00 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
• C07B 61/00 - Other general methods
• C07C 31/04 - Methanol

Abstract

Provided are: a phosphorylation promoter for extracellular signal-regulated kinases (ERK) and a binding inhibitor for inhibiting the binding of a WD repeat-containing protein 5 (WDR5) to an IQ motif-containing GTPase-activating protein 1 (IQGAP1), which can be effectively used for treating cognitive impairment or the like by inhibiting the binding of WDR5 to IQGAP1 and by promoting phosphorylation of ERK; and a pharmaceutical composition comprising the promoter and the inhibitor, where the composition is for the treatment of chronic kidney disease (CKD)-induced cognitive impairment. Provided are: the phosphorylation promoter and the binding inhibitor that contain, as an active ingredient, rabeprazole, a rabeprazole derivative or a salt thereof; and the pharmaceutical composition comprising the phosphorylation promotor and the binding inhibitor.

IPC Classes  ?

• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

A metal recovery apparatus including a leaching unit that directly leaches a metal element contained in a composition into a hydrophobic deep eutectic solvent and a recovery unit that separates and recovers the metal element from the deep eutectic solvent, wherein the metal element-containing composition is solid at 25° C. and does not contain an inorganic acid, the metal element is a metal, a metal compound, or metal ions, and the deep eutectic solvent does not contain an inorganic acid.

IPC Classes  ?

• C22B 3/02 - Apparatus therefor
• C22B 3/00 - Extraction of metal compounds from ores or concentrates by wet processes
• C22B 3/16 - Extraction of metal compounds from ores or concentrates by wet processes by leaching in organic solutions
• C22B 3/20 - Treatment or purification of solutions, e.g. obtained by leaching
• C22B 11/00 - Obtaining noble metals
• C22B 26/12 - Obtaining lithium

Abstract

A crosslinkable polymer composition which provides a crosslinked product capable of both heat resistance and re-formability, a crosslinked polymer material capable of both heat resistance and re-formability, and an insulated wire and a wiring harness including the crosslinked polymer material. The crosslinkable polymer composition includes: ingredient A from which metal ion is released by heat; and ingredient B including an organic polymer having a side chain, including an electron-withdrawing substituent group capable of forming an ionic bond with the metal ion, and when B is crosslinked via the metal ion to form a crosslinked product, the product has a flow starting temperature of 190° C. or higher and 300° C. or lower. The crosslinked polymer material includes the crosslinked product of the crosslinkable polymer composition. The insulated wire includes a wire conductor, and an insulation coating including the crosslinked polymer material, and the wiring harness including the insulated wire.

IPC Classes  ?

• C08F 8/42 - Introducing metal atoms or metal-containing groups
• H01B 3/44 - Insulators or insulating bodies characterised by the insulating materialsSelection of materials for their insulating or dielectric properties mainly consisting of organic substances plasticsInsulators or insulating bodies characterised by the insulating materialsSelection of materials for their insulating or dielectric properties mainly consisting of organic substances resinsInsulators or insulating bodies characterised by the insulating materialsSelection of materials for their insulating or dielectric properties mainly consisting of organic substances waxes vinyl resinsInsulators or insulating bodies characterised by the insulating materialsSelection of materials for their insulating or dielectric properties mainly consisting of organic substances plasticsInsulators or insulating bodies characterised by the insulating materialsSelection of materials for their insulating or dielectric properties mainly consisting of organic substances resinsInsulators or insulating bodies characterised by the insulating materialsSelection of materials for their insulating or dielectric properties mainly consisting of organic substances waxes acrylic resins
• H01B 7/00 - Insulated conductors or cables characterised by their form

Abstract

An organic electroluminescent device having a structure of at least an anode 2, a light-emitting layer 3 and a cathode 4 layered in that order, wherein the light-emitting layer 3 contains a first host material, a second host material and a light-emitting material of a dopant, and both the first host material and the second host material have a lowest excited triplet energy level higher than the lowest excited triplet energy level of the light-emitting material. The device is protected from performance deterioration with time in driving and has a long lifetime.

IPC Classes  ?

• H10K 50/12 - OLEDs or polymer light-emitting diodes [PLED] characterised by the electroluminescent [EL] layers comprising dopants
• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• H10K 50/11 - OLEDs or polymer light-emitting diodes [PLED] characterised by the electroluminescent [EL] layers
• H10K 50/15 - Hole transporting layers
• H10K 50/16 - Electron transporting layers
• H10K 50/18 - Carrier blocking layers
• H10K 50/81 - Anodes
• H10K 50/82 - Cathodes
• H10K 85/60 - Organic compounds having low molecular weight
• H10K 101/00 - Properties of the organic materials covered by group
• H10K 101/10 - Triplet emission

Abstract

Provided is a mineral processing method that allows obtaining a concentrate having a low arsenic grade from a raw material having a high arsenic grade. The mineral processing method includes: a repulping step of adding water to a raw material containing a non-arsenic-containing sulfide mineral as a sulfide mineral not containing arsenic and an arsenic-containing sulfide mineral as a copper sulfide mineral containing arsenic to obtain a mineral slurry; a pH adjusting step of adjusting a pH of a liquid phase of the mineral slurry to 10 or more; a conditioning step of adding an oxidant and xanthate alkali metal salt to the mineral slurry; and a flotation step of performing flotation using the mineral slurry to separate the raw material into a floating ore having a grade of the non-arsenic-containing sulfide mineral higher than a grade of the non-arsenic-containing sulfide mineral of the raw material and a precipitating ore having a grade of the arsenic-containing sulfide mineral higher than a grade of the arsenic-containing sulfide mineral of the raw material. The raw material contains the arsenic by 4.4 to 5.8 pts. wt. per 100 pts. wt. of copper.

IPC Classes  ?

• C22B 1/11 - Removing sulfur, phosphorus or arsenic, other than by roasting
• C22B 15/00 - Obtaining copper

Abstract

Provided are: a liquid processing method characterized by including a plasma irradiation step for irradiating a liquid adhering to a substrate having a fine structure formed thereon with plasma; and a liquid processing device characterized by being provided with a plasma irradiation unit that irradiates a liquid adhering to a substrate with plasma.

IPC Classes  ?

• H01L 21/304 - Mechanical treatment, e.g. grinding, polishing, cutting

Abstract

The present invention provides a biomarker for non-muscle invasive bladder cancer, wherein the biomarker is one or multiple mutations in a protein encoded by the ADGRG6 enhancer.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism

Abstract

This polarization source for dynamic nuclear polarization comprises fullerene having an added substituent, has high dynamic nuclear polarization efficiency, and excellent oxygen resistance. Examples of the substituent include a substituent having a hydrocarbon group or an oxycarbonyl structure. It is preferable that the substituent is a divalent group having bonds which are bonded to each of two adjacent ring-skeleton-constituting atoms of the fullerene.

IPC Classes  ?

• G01N 24/12 - Investigating or analysing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using double resonance
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• G01R 33/46 - NMR spectroscopy

Abstract

This organic EL element, which is obtained using a compound represented by general formula (1), can serve as an organic EL element that exhibits high luminous efficiency and has a long service life. The compound for an organic electroluminescent element is represented by general formula (1). Here, Ad is an adamantyl group represented by general formula (2). X moieties are each independently N or CR1, and at least one X moiety is N. R1moieties are each independently hydrogen or the like.　Ar1is a substituted or unsubstituted aromatic hydrocarbon group having 6-18 carbon atoms, or the like.　R moieties are each independently a substituted or unsubstituted aromatic heterocyclic group having 3-17 carbon atoms, or the like.　L1and L2 are each independently a direct bond or the like.　a denotes a number of substituent groups, and each independent value of a is an integer between 0 and 4. b to f denote numbers of substituent groups, and each independent value of b to f is an integer between 0 and 4. However, b+c+d+e+f≥1.

IPC Classes  ?

• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• H10K 50/12 - OLEDs or polymer light-emitting diodes [PLED] characterised by the electroluminescent [EL] layers comprising dopants
• H10K 85/60 - Organic compounds having low molecular weight
• H10K 101/30 - Highest occupied molecular orbital [HOMO], lowest unoccupied molecular orbital [LUMO] or Fermi energy values
• H10K 101/40 - Interrelation of parameters between multiple constituent active layers or sublayers, e.g. HOMO values in adjacent layers

Abstract

The present invention addresses the problem of providing a steam electrolysis device and a steam electrolysis method that achieve high energy efficiency. The present invention relates to a steam electrolysis device and a steam electrolysis method. The steam electrolysis device is provided with an anode electrode chamber, a cathode electrode chamber, and an ion conductor disposed between the electrode chambers, wherein steam more than twice a hydrogen generation amount is supplied to at least one selected from the anode electrode chamber and the cathode electrode chamber, and 50% or less of the charged steam is electrolyzed.

IPC Classes  ?

• C25B 9/00 - Cells or assemblies of cellsConstructional parts of cellsAssemblies of constructional parts, e.g. electrode-diaphragm assembliesProcess-related cell features
• C25B 1/042 - Hydrogen or oxygen by electrolysis of water by electrolysis of steam
• C25B 9/60 - Constructional parts of cells
• C25B 13/04 - DiaphragmsSpacing elements characterised by the material
• C25B 13/07 - DiaphragmsSpacing elements characterised by the material based on inorganic materials based on ceramics
• C25B 15/08 - Supplying or removing reactants or electrolytesRegeneration of electrolytes
• C25B 15/021 - Process control or regulation of heating or cooling

Abstract

Provided is a pharmaceutical composition for treating or preventing infections with Shiga toxin-producing bacteria, the pharmaceutical composition comprising: a crosslinked polymer in which a random copolymer having a constituent unit (a1) comprising a Shiga toxin-binding oligosaccharide and at least one another constituent unit is crosslinked; and a pharmaceutically acceptable carrier. The pharmaceutical composition is intended to be administered in combination with an antibiotic composition.

IPC Classes  ?

• A61K 31/785 - Polymers containing nitrogen
• A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 47/61 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
• A61P 31/04 - Antibacterial agents

Abstract

The present invention provides a biomarker which is for bladder cancer and which has a variation in one base in a WDR74 promoter or in a transcription product thereof.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
• C12N 15/09 - Recombinant DNA-technology
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12Q 1/6869 - Methods for sequencing

Abstract

This composite includes: activated carbon that has a specific surface area of 1400 m2/g or greater and satisfies one or both of the following conditions (A) and (B); and at least one of elemental sulfur and a discharge product of elemental sulfur. (A) The peak width of the D band in the Raman spectrum of the activated carbon is 100 cm-1or less. (B) The peak width of the G band in the Raman spectrum of the activated carbon is 70 cm-1 or less.

IPC Classes  ?

• H01M 4/38 - Selection of substances as active materials, active masses, active liquids of elements or alloys
• C01B 25/14 - Sulfur, selenium, or tellurium compounds of phosphorus
• C01B 32/354 - After-treatment
• H01B 1/06 - Conductors or conductive bodies characterised by the conductive materialsSelection of materials as conductors mainly consisting of other non-metallic substances
• H01B 1/10 - Conductors or conductive bodies characterised by the conductive materialsSelection of materials as conductors mainly consisting of other non-metallic substances sulfides
• H01M 4/136 - Electrodes based on inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFy
• H01M 4/36 - Selection of substances as active materials, active masses, active liquids
• H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers

Abstract

A medical coating agent according to the present invention contains a polymer that includes a structural unit (M1) that is derived from an ethylenically unsaturated monomer that has a urethane linkage or a urea linkage and a structural unit (M2) that has a homopolymer SP value of no more than 10.0 and is derived from an ethylenically unsaturated monomer that has an alkyl group (that is not the alkyl group of an alkoxyalkyl group) or an alkoxyalkyl group.

IPC Classes  ?

• A61L 33/06 - Use of macromolecular materials
• A61L 27/34 - Macromolecular materials
• A61L 29/08 - Materials for coatings
• A61L 31/10 - Macromolecular materials

Abstract

Provided are: a gas diffusion composite material for fuel cells which is a thin layer and in which electric resistance such as contact resistance is reduced; and a solid polymer fuel cell comprising the same.　This gas diffusion composite material for fuel cells: has a porous base material sheet made of an electrically conductive material, and a fine porous carbon layer that contains a water repellent resin and a particulate and/or fibrous carbon material; and has either one of structures (A) to (E).　Structure (A): A structure in which the fine porous carbon layer covers one surface of the porous base material sheet. Structure (B): A structure in which the fine porous carbon layer covers both surfaces of the porous base material sheet. Structure (C): A structure in which the fine porous carbon layer covers one surface of the porous base material sheet, and a portion thereof enters the inside of the porous base material sheet. Structure (D): A structure in which the fine porous carbon layer covers one surface of the porous base material sheet, and a portion of the fine porous carbon layer enters the inside of the porous base material sheet, and in which the fine porous carbon layer reaches the opposite surface of the porous base material sheet from the one surface thereof. Structure (E): A structure in which the entirety of the porous base material sheet is embedded in the fine porous carbon layer.

IPC Classes  ?

• H01M 4/96 - Carbon-based electrodes
• H01M 8/10 - Fuel cells with solid electrolytes

Abstract

Provided is a method for controlling transcription of RNA, the method comprising a step of transcribing the RNA from an expression vector of RNA. The RNA has one or more nucleotide residues added to the 5' end. Also provided is a method for designing an expression vector of RNA, the method comprising adjusting one or more selected from the number of nucleotide residues added to the 5' end of the RNA coding sequence and the types of the nucleotide residues to design an expression vector of RNA in which the transcription efficiency of the RNA is controlled.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 9/22 - Ribonucleases
• C12N 15/55 - Hydrolases (3)
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression

Abstract

Disclosed is an enhancer of the physiological activity of a hepatocyte growth factor, the enhancer comprising a trisulfide compound. The trisulfide compound comprises at least one component selected from the group consisting of glutathione trisulfide, a pharmaceutically acceptable salt of glutathione trisulfide, a compound represented by formula (1), a pharmaceutically acceptable salt of the compound, a cyclodextrin inclusion complex of the compound or the pharmaceutically acceptable salt, a compound represented by formula (6), a pharmaceutically acceptable salt of the compound, and a cyclodextrin inclusion complex of the compound or the pharmaceutically acceptable salt.　

IPC Classes  ?

• A61K 31/385 - Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
• A61K 38/06 - Tripeptides
• A61K 38/19 - CytokinesLymphokinesInterferons
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

A photon upconversion particle according to the present invention comprises a photon upconversion composition and a polymer, and has a particle diameter of 100-2000nm. Herein, the photon upconversion composition is dispersed in the polymer.

IPC Classes  ?

• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• C08L 25/04 - Homopolymers or copolymers of styrene
• C08L 83/04 - Polysiloxanes
• C08L 101/00 - Compositions of unspecified macromolecular compounds

Abstract

This core-shell particle comprises a core made of copper, and a shell containing an alloy of copper and a metal M1 other than copper, wherein, according to a powder X-ray diffraction measurement of the core-shell particle using CuKα radiation, a diffraction peak with a maximum height is within a range of 2θ = 43 ± 1°, the core-shell particle having a polygonal shape other than a cube. Alternatively, this core-shell particle comprises a core made of copper and a shell containing an alloy of copper and a metal M2 other than copper (except for silver), wherein, according to a powder X-ray diffraction measurement of the core-shell particle using CuKα radiation, a diffraction peak with a maximum height is within a range of 2θ = 43 ± 1°, the core-shell particle having a polygonal shape.

IPC Classes  ?

• B22F 1/17 - Metallic particles coated with metal
• B22F 1/00 - Metallic powderTreatment of metallic powder, e.g. to facilitate working or to improve properties
• C25B 1/02 - Hydrogen or oxygen
• C25B 1/23 - Carbon monoxide or syngas
• C25B 3/03 - Acyclic or carbocyclic hydrocarbons
• C25B 3/07 - Oxygen containing compounds

Abstract

In the thiol production method according to the present embodiment, thiol (2) is obtained by reacting an alkene (1) or a derivative thereof with sulfur in the presence of hydrogen and a metal element.

IPC Classes  ?

• C07C 319/02 - Preparation of thiols, sulfides, hydropolysulfides or polysulfides of thiols
• C07B 61/00 - Other general methods
• C07C 321/04 - Thiols having mercapto groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
• C07C 321/06 - Thiols having mercapto groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
• C07C 321/10 - Thiols having mercapto groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
• C07C 321/22 - Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of rings other than six-membered aromatic rings

Abstract

A method for producing mesophase pitch, the method comprising: an A step in which heavy residual oil is subjected to a pressurizing heat treatment and then subjected to an inert gas blowing heat treatment to prepare pitch component a, which contains a mesogen component that is an optically anisotropic component and a solvent component that is an optically isotropic component; a B step in which heavy residual oil is subjected to a pressurizing heat treatment and then subjected to an inert gas blowing heat treatment to prepare pitch component a', which contains a mesogen component that is an optically anisotropic component and a solvent component that is an optically isotropic component, and the mesogen component is separated from pitch component a' to acquire pitch component B, which is mainly a mesogen component; and a C step in which the pitch component a, which was acquired in the A step and which includes a mesogen component and a solvent component, and the pitch component b, which was acquired in the B step and which is mainly a mesogen component, are mixed and subjected to heat treatment.

IPC Classes  ?

• D01F 9/155 - Carbon filamentsApparatus specially adapted for the manufacture thereof by decomposition of organic filaments from pitch or distillation residues from petroleum pitch
• C10C 3/02 - Working-up pitch, asphalt, bitumen by chemical means
• C10C 3/04 - Working-up pitch, asphalt, bitumen by chemical means by blowing or oxidising
• C10C 3/06 - Working-up pitch, asphalt, bitumen by distillation
• C10C 3/08 - Working-up pitch, asphalt, bitumen by selective extraction
• D01F 9/14 - Carbon filamentsApparatus specially adapted for the manufacture thereof by decomposition of organic filaments

Abstract

The present invention relates to a scaffold material containing a cellulose nanofiber (CNF) into which an ionic functional group has been introduced, a cell culture substrate having the scaffold material on the surface thereof, and a method for culturing cells such as stem cells using the same.

IPC Classes  ?

• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
• C12N 5/07 - Animal cells or tissues
• C12N 5/074 - Adult stem cells
• C12N 5/0735 - Embryonic stem cellsEmbryonic germ cells
• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
• C12N 5/0789 - Stem cellsMultipotent progenitor cells
• C12N 5/0797 - Stem cellsProgenitor cells

Abstract

Provided is a dendritic cell activator that contains, as an active ingredient, a component derived from a natural product which has been eaten for many years and the safety of which has been empirically confirmed, and that is used for inducing or promoting an acquired immune response effective against cancer or infectious disease.　Specifically provided are: a dendritic cell activator containing, as an active ingredient, 5-(3,5-dihydroxyphenyl)-γ-valerolactone represented by formula (I); and a medicine, a supplement, and a food or beverage each containing the compound represented by formula (I) as an active ingredient. [The configuration of the wavy line may be either R-form or S-form.]

IPC Classes  ?

• A61K 31/365 - Lactones
• A61P 35/00 - Antineoplastic agents
• A61P 37/04 - Immunostimulants
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

Provided is a production method that enables simple and efficient production of a fluorinated hydrocarbon by a gas phase flow method without using a catalyst. The method of producing a fluorinated hydrocarbon includes continuously supplying a gaseous fluorine-containing inorganic compound to an electrical discharge zone in a plasma apparatus and subsequently causing migration to outside of the electrical discharge zone in the plasma apparatus, continuously supplying a feedstock gas containing an inert gas and a compound represented by formula 1: CH3—R (R is a hydrogen atom, a chlorine atom, a bromine atom, an iodine atom, or an organic group other than a hydrocarbon group) to outside of the electrical discharge zone in the plasma apparatus, and subsequently continuously releasing, to outside of the plasma apparatus, gas that is contained outside of the electrical discharge zone in the plasma apparatus.

IPC Classes  ?

• C07C 17/16 - Preparation of halogenated hydrocarbons by replacement by halogens of hydroxyl groups
• C07C 17/10 - Preparation of halogenated hydrocarbons by replacement by halogens of hydrogen atoms
• C07C 17/361 - Preparation of halogenated hydrocarbons by reactions involving a decrease in the number of carbon atoms
• C07C 17/363 - Preparation of halogenated hydrocarbons by reactions involving a decrease in the number of carbon atoms by elimination of carboxyl groups

Abstract

The present invention addresses the problem of providing: a solid-liquid extraction agent that can efficiently extract PGMs directly from a PGM-containing solid article such as an automobile catalyst or a PGM-containing solid composition without using a highly concentrated inorganic acid; and an extraction method using said extraction agent.　The present invention relates to: (a) a solid-liquid extraction agent for a platinum group metal, the agent containing a hydrophobic deep eutectic solvent; and a solid-liquid extraction method for a platinum group metal using said extraction agent.

IPC Classes  ?

• C22B 11/00 - Obtaining noble metals
• C22B 3/16 - Extraction of metal compounds from ores or concentrates by wet processes by leaching in organic solutions

Abstract

The present invention aims at therapeutics to treat and/or prevent Rett syndrome (RTT), autism spectrum disorders or schizophrenia for which no curative therapy has yet been found. The present invention aims at therapeutics to treat and/or prevent Rett syndrome (RTT), autism spectrum disorders or schizophrenia for which no curative therapy has yet been found. The invention relates to pharmaceutical compositions for preventing or treating Rett syndrome (RTT), autism spectrum disorders, or schizophrenia, which comprises a reverse transcription inhibitor for retrotransposon L1.

IPC Classes  ?

• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine

Abstract

The purpose of the present invention is to form a ferroelectric thin film that exhibits a high electro-optic effect on a substrate composed of an amorphous material. The present invention relates to a structure (10) comprising: a substrate (2) composed of an amorphous material; a seed layer (4) laminated on the substrate (2); and a PZT thin film, a PLZT thin film, a BTO thin film, or a BSTO thin film (6) laminated on the seed layer (4). The structure (10) has a light propagation loss of 1 db/mm or less when calculated using a prescribed measuring method.

IPC Classes  ?

• G02F 1/05 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour based on ceramics or electro-optical crystals, e.g. exhibiting Pockels or Kerr effect with ferro-electric properties

Abstract

Provided are a crosslinkable polymer composition capable of forming cross-linkage by heating and capable of undergoing, at a certain temperature, transition from the state with low shape change by heat to the state with high shape change by heat, a crosslinked polymer material obtained by cross-linking the crosslinkable polymer composition and an insulated electric wire and a wire harness comprising the crosslinked polymer material.　This crosslinkable polymer composition comprises: a component A capable of releasing a metal ion by heat; a component B formed with an organic polymer having a side chain and, in the side chain, an electron-attracting substituent capable of forming an ionic bond with the metal ion released from the component A; and a component C formed with a compound having the structure represented by formula (1) and having a melting point of 190°C or higher, and a cross-linked substance obtained by crosslinking the component B with the metal ion released from the component A has a flow-starting temperature of 190°C or higher.　R represents a hydrogen atom or a hydroxy group. m+n is 11-30 inclusive and My+ represents a y-valent metal ion.

IPC Classes  ?

• C08L 101/02 - Compositions of unspecified macromolecular compounds characterised by the presence of specified groups
• C08K 5/098 - Metal salts of carboxylic acids
• H01B 7/00 - Insulated conductors or cables characterised by their form
• H01B 7/02 - Disposition of insulation

Abstract

1233 represents a hydrocarbon group having 13-30 (inclusive) carbon atoms.

IPC Classes  ?

• C08L 101/02 - Compositions of unspecified macromolecular compounds characterised by the presence of specified groups
• C08K 5/17 - AminesQuaternary ammonium compounds
• H01B 7/00 - Insulated conductors or cables characterised by their form
• H01B 7/02 - Disposition of insulation

Abstract

The present disclosure provides: a cell which can be differentiated into an M2 macrophage in a tumor tissue and has a property such that an M2 macrophage differentiated from the cell can express an inflammatory cytokine; and a composition containing the cell.

IPC Classes  ?

• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
• A61P 35/00 - Antineoplastic agents
• C12N 15/19 - InterferonsLymphokinesCytokines
• C12N 15/28 - Tumor necrosis factors
• C12N 5/0786 - MonocytesMacrophages

Abstract

A pharmaceutical composition for neurological diseases and a food composition for ameliorating neurological diseases are provided utilizing micro-RNA capable of suppressing the expression of a specific gene of which the expression is induced in neurological diseases. The composition according to the present invention contains micro-RNA comprising the nucleotide sequence represented by SEQ ID NO:1 or a nucleotide sequence having 85% or higher identity to the nucleotide sequence represented by SEQ ID NO:1.

IPC Classes  ?

• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A23F 3/14 - Tea preparations, e.g. using additives
• A23F 3/22 - Drying or concentrating tea extract
• A23L 33/13 - Nucleic acids or derivatives thereof
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/24 - Antidepressants
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/22 - Beta-interferons

Abstract

Provided is a method for producing an agglomerate which has carbon as a principal component thereof, has high density and high strength, and is produced from a carbon-containing material having a high concentration of coal or a coal derivative and poor caking properties. This method for producing an agglomerate having carbon as a principal component thereof involves: a pulverization step for obtaining coal dust having a maximum particle diameter of 300μm or less by pulverizing coal in an amount greater than or equal to 1 mass% and less than 20 mass% with volatile matter as a dry basis; and a hot-pressing step for obtaining an agglomerate by pressure-molding the coal dust at a temperature included in the temperature range of 600-1250°C, inclusive, in an oxygen-less environment.

IPC Classes  ?

• C04B 35/528 - Shaped ceramic products characterised by their compositionCeramic compositionsProcessing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on non-oxides based on carbon, e.g. graphite obtained from carbonaceous particles with or without other non-organic components
• C04B 35/645 - Pressure sintering
• C10B 53/08 - Destructive distillation, specially adapted for particular solid raw materials or solid raw materials in special form in the form of briquettes, lumps or the like

Abstract

ICIC of 50 MPa∙m1/2 or more in both an air atmosphere and a hydrogen atmosphere.

IPC Classes  ?

• C22C 9/00 - Alloys based on copper
• C22C 9/06 - Alloys based on copper with nickel or cobalt as the next major constituent
• C22F 1/00 - Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working
• C22F 1/08 - Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working of copper or alloys based thereon

Abstract

Provided is a superconducting cable and an electric propulsion system equipped with the superconducting cable, said cable capable of achieving simplified overall configuration and weight reduction while ensuring high current carrying performance. The superconducting cable comprises: a heat insulating pipe having an internal space for circulating a refrigerant during use; and a plurality of superconducting laminated conductors that are arranged in a multi-core structure within the internal space and are insulated from one another, and that are each a laminated body formed by stacking a plurality of tape-shaped superconducting wires. The heat insulating pipe is made of a resin.

IPC Classes  ?

• H01B 12/16 - Superconductive or hyperconductive conductors, cables or transmission lines characterised by cooling
• H01B 12/06 - Films or wires on bases or cores

Abstract

Provided are: a novel variable bone graft substitute for medical use, the bone graft substitute being easy to handle, capable of adapting to the shape of a bone defect during filling, and having good bone formability; and a manufacturing method therefor. Specifically, provided are: a variable bone graft substitute for medical use provided with a chain-type connected body in which a plurality of ceramic rings are connected together; and a manufacturing method therefor.

IPC Classes  ?

• A61L 27/10 - Ceramics or glasses
• A61F 2/28 - Bones
• A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof

Abstract

Provided is a feature for identifying a marker protein in sensory nerve tissue and preventing or treating neuropathic pain.　The present invention pertains to an agent for preventing or treating neuropathic pain, containing, as an active ingredient, a semaphorin 3E (SEMA3E) inhibitor, e.g. a substance that inhibits the expression of the SEMA3E gene, in particular siRNA, antisense, and ribozyme corresponding to the SEMA3E gene, or a substance that specifically binds to the SEMA3E protein, in particular antibodies, antibody fragments, or aptamers for the SEMA3E protein.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 25/04 - Centrally acting analgesics, e.g. opioids
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12Q 1/6813 - Hybridisation assays
• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
• G01N 33/15 - Medicinal preparations
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention provides a method for producing a nitrogenated compound, the method including a step of synthesizing the nitrogenated compound from nitrogen and a proton source in the presence of a nitrogen activation catalyst having a structure represented by any one of formulae (I-1) to (I-4). [In the formulae, R1to R5, n1, n2, m1, m2, m3, m4 and Z are as defined in the description.]

IPC Classes  ?

• B01J 31/22 - Organic complexes
• C01C 1/04 - Preparation of ammonia by synthesis

Abstract

The ammonia synthesis catalyst of the present invention is a complex containing metal ions and a ligand that contains an aromatic polycyclic structure.

IPC Classes  ?

• B01J 31/22 - Organic complexes
• C01C 1/04 - Preparation of ammonia by synthesis

Abstract

A carbon monoxide gas sensor is a single-chamber sensor for measuring the carbon monoxide gas concentration in a gas phase. The carbon monoxide gas sensor has electrodes disposed on respective sides of a solid electrolyte layer. One of the electrodes is active for oxidation of carbon monoxide gas, and the other of the electrodes is more inactive for oxidation of carbon monoxide gas than the one electrode. The carbon monoxide gas sensor is configured to measure a short-circuit current between the electrodes. In the carbon monoxide gas sensor, the solid electrolyte layer has oxide ion conductivity.

IPC Classes  ?

• G01N 27/407 - Cells and probes with solid electrolytes for investigating or analysing gases

Abstract

The present invention addresses the problem of providing an all-solid-state lithium-ion secondary battery that comprises an oxide-based solid electrolyte layer and has a large capacitance and excellent battery characteristics. The present invention relates to an all-solid-state lithium-ion secondary battery in which a solid electrolyte layer is provided between a positive electrode and a negative electrode, and the solid electrolyte layer includes a lithium-ion conductive oxide and at least one selected from NiO and Ni.

IPC Classes  ?

• H01M 10/0562 - Solid materials
• H01B 1/06 - Conductors or conductive bodies characterised by the conductive materialsSelection of materials as conductors mainly consisting of other non-metallic substances
• H01M 4/131 - Electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx
• H01M 10/052 - Li-accumulators
• H01M 10/0585 - Construction or manufacture of accumulators having only flat construction elements, i.e. flat positive electrodes, flat negative electrodes and flat separators

Abstract

abcde444434444, a satisfies 0.3 ≤ a ≤ 3.0, b satisfies 0.75 ≤ b ≤ 1.0, c satisfies 0 ≤ c ≤ 0.25, d satisfies 3.5 ≤ b ≤ 6.0 and e satisfies 0.15 ≤ b ≤ 0.67.

IPC Classes  ?

• H01B 1/10 - Conductors or conductive bodies characterised by the conductive materialsSelection of materials as conductors mainly consisting of other non-metallic substances sulfides
• H01B 1/06 - Conductors or conductive bodies characterised by the conductive materialsSelection of materials as conductors mainly consisting of other non-metallic substances
• H01B 1/08 - Conductors or conductive bodies characterised by the conductive materialsSelection of materials as conductors mainly consisting of other non-metallic substances oxides
• H01M 10/0562 - Solid materials

Abstract

This image conversion device (10) comprises: a storage unit (14) that stores a model for generating, from an input image obtained through a first nuclear radiology examination in which a radioactive substance is administered to a body, a simulated output image that simulates being obtained through a second nuclear radiology examination in which a radioactive substance is administered to the body and which is different from the first nuclear radiology examination, the simulated output image being created through machine learning using a dataset that includes a first training image obtained through the first nuclear radiology examination and a second training image obtained through the second nuclear radiology examination; an acquisition unit (15) that acquires, for an organ of a patient, an original image obtained through the first nuclear radiology examination; an image generation unit (16) that inputs the original image to the model to thereby generate, for the organ of the patient, a simulated image that simulates being obtained through the second nuclear radiology examination; and an output unit (17) that outputs the simulated image.

IPC Classes  ?

• G01T 1/161 - Applications in the field of nuclear medicine, e.g. in vivo counting
• G01T 1/164 - Scintigraphy
• G06T 1/00 - General purpose image data processing
• G06T 7/00 - Image analysis
• G06V 10/70 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning

Abstract

In this electrochemical reduction method, CO2 is electrochemically reduced in a state where a solution having a pH of 5 to 15 and the CO2 have been brought into contact with a catalyst containing an oxide containing Ti.

IPC Classes  ?

• C25B 11/042 - Electrodes formed of a single material
• C25B 3/03 - Acyclic or carbocyclic hydrocarbons
• C25B 3/26 - Reduction of carbon dioxide

Abstract

22 (R represents a hydrocarbon group having 1-20 carbon atoms), and carbon monoxide in the presence of a catalyst including rhodium or cobalt. (In formula (1), R represents a hydrocarbon group having 1-20 carbon atoms.)

IPC Classes  ?

• C07C 231/10 - Preparation of carboxylic acid amides from compounds not provided for in groups
• C07C 235/06 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
• C07B 61/00 - Other general methods

Abstract

The present invention addresses the problem of providing a laminate in which rubber layers are bonded to each other with sufficient adhesive strength and which has sufficient strength. The solution is a laminate (1) of a rubber layer (A) (2) and a rubber layer (B) (3), the laminate being characterized in that: the rubber layer (A) (2) is composed of a rubber composition containing a rubber component and a metal salt containing Group 3-12 elements of the periodic table; the rubber component includes a modified diene-based rubber formed by modifying a diene-based rubber with a tetrazine derivative of general formula (1) [in the formula, X1and X2are each independently a pyridyl group or a pyrimidinyl group, and Y1and Y2 are each independently a single bond or a divalent hydrocarbon group]; said modified diene-based rubber is modified by blending at least 1 mol% of the tetrazine derivative with respect to the diene monomer unit of the diene-based rubber; and the content of the metal salt in the rubber composition is 10-60 parts by mass with respect to 100 parts by mass of the rubber component.

IPC Classes  ?

• B32B 25/16 - Layered products essentially comprising natural or synthetic rubber comprising polydienes or poly-halodienes
• B60C 1/00 - Tyres characterised by the chemical composition or the physical arrangement or mixture of the composition
• B60C 11/02 - Replaceable treads
• C08K 5/09 - Carboxylic acidsMetal salts thereofAnhydrides thereof
• C08K 5/14 - Peroxides
• C08L 15/00 - Compositions of rubber derivatives

Abstract

A method of easily producing an immunogenic pupa for oral administration and a pupa for oral administration produced by the method are provided. The method is a method of producing a pupa for oral administration, including a step of infecting a larva or pupa of an insect capable of being baculovirus-infected with a recombinant baculovirus having DNA encoding an antigen protein introduced therein and freeze-drying a pupa having pupated from the infected larva or the infected pupa.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61K 35/64 - Insects, e.g. bees, wasps or fleas
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 31/20 - Antivirals for DNA viruses
• A61P 37/04 - Immunostimulants
• C12N 15/86 - Viral vectors

Abstract

[OBJECT] [OBJECT] The object of the present invention is to provide an ingredient for inhibiting wrinkle with excellent safety. [OBJECT] The object of the present invention is to provide an ingredient for inhibiting wrinkle with excellent safety. [MEANS FOR SOLUTION] [OBJECT] The object of the present invention is to provide an ingredient for inhibiting wrinkle with excellent safety. [MEANS FOR SOLUTION] The problem can be solved by a composition for inhibiting wrinkle, comprising β-alanine or a salt thereof as an active ingredient, of the present invention.

IPC Classes  ?

• A61K 8/44 - Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfurSalts, esters or N-acylated derivatives thereof
• A61K 8/98 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution of animal origin
• A61Q 19/08 - Anti-ageing preparations

Abstract

An immunogenic complex comprising an antigen and a mannoprotein, wherein said antigen and mannoprotein are linked by a disulfide bond. A pharmaceutical composition comprising said immunogenic complex.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/35 - Allergens
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61P 37/02 - Immunomodulators

Abstract

This agent for increasing brain plasmalogen contains a compound represented by formula (I), a racemic body thereof, or a salt of those. [In formula (I), X represents a carbon atom or an oxygen atom, R1represents a saturated aliphatic hydrocarbon group optionally containing a cyclic structure, and R2 represents a C10-30 saturated or unsaturated aliphatic hydrocarbon group optionally having a C1-4 alkyl group or a C1-4 alkoxy group as a substitution group.]

IPC Classes  ?

• A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 25/24 - Antidepressants
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

Provided is a widely applicable and safe prophylactic agent or therapeutic agent for adverse reaction of an anthracycline anticancer agent. In cancer treatment with an anthracycline anticancer agent, 5-aminolevulinic acids are used in combination therewith.

IPC Classes  ?

• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 33/26 - IronCompounds thereof

Abstract

A method for producing ovarian somatic cell-like cells includes (1) culturing primate pluripotent stem cells in a medium including a GSK3 inhibitor and a ROCK inhibitor; (2) culturing the cells from the (1) culturing in a medium including BMP4, retinoic acid, and an MEK inhibitor; and (3) culturing the cells from the (2) culturing in a base medium to obtain ovarian somatic cell-like cells. A method for inducing the differentiation of primate pluripotent stem cells into ovarian somatic cell-like cells includes inducing the differentiation of primate pluripotent stem cells into ovarian somatic cell-like cells using the method for producing ovarian somatic cell-like cells.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

A floating body (4) for a spar-type offshore wind power generation facility floating sideways is raised by injecting ballast water at sea, by steps including a first step of decentering a center of gravity of the floating body for the spar-type offshore wind power generation facility by means of a center-of-gravity decentering device, and a second step of injecting the ballast water to raise upright the floating body for the spar-type offshore wind power generation facility. The center-of-gravity decentering device may be a weight (2) attached to an outer surface of the floating body, or a solid ballast (34) introduced in the floating body.

IPC Classes  ?

• B63B 39/03 - Equipment to decrease pitch, roll, or like unwanted vessel movementsApparatus for indicating vessel attitude to decrease vessel movements by displacement of masses by transferring liquids
• B63B 35/44 - Floating buildings, stores, drilling platforms, or workshops, e.g. carrying water-oil separating devices
• B63B 77/10 - Transporting or installing offshore structures on site using buoyancy forces, e.g. using semi-submersible barges, ballasting the structure or transporting of oil-and-gas platforms specially adapted for electric power plants, e.g. wind turbines or tidal turbine generators
• F03D 13/25 - Arrangements for mounting or supporting wind motorsMasts or towers for wind motors specially adapted for offshore installation

Abstract

Provided is a method for producing a compound having a dicarboxylic acid derivative structure, the method comprising a reaction step in which olefin, alcohol, carbon monoxide, and oxygen are reacted in the presence of ammonium salt and a heterogeneous catalyst comprising a carrier with a palladium-containing compound supported thereon. The ammonium salt is preferably ammonium chloride. The olefin is preferably alicyclic olefin.

IPC Classes  ?

• C07C 67/38 - Preparation of carboxylic acid esters by reaction with carbon monoxide or formates by addition to an unsaturated carbon-to-carbon bond
• B01J 23/44 - Palladium
• C07B 61/00 - Other general methods
• C07C 69/753 - Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring of polycyclic acids

Abstract

Provided is a medical composition capable of imparting biocompatibility to the surface of a medical instrument etc. and application of the medical composition. In an embodiment of the present invention, the medical composition contains a urethane resin, and the urethane resin has urethane bonds in the main chain and a polyoxyethylene structure in the main chain and/or side chains. In another embodiment of the present invention, the urethane resin has a structural unit derived from a polycarbonate polyol and a structural unit derived from an aliphatic isocyanate and also has at least one urea bond.

IPC Classes  ?

• A61L 33/06 - Use of macromolecular materials
• A61L 33/00 - Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of bloodMaterials for such treatment
• C08G 18/08 - Processes
• C08G 18/10 - Prepolymer processes involving reaction of isocyanates or isothiocyanates with compounds having active hydrogen in a first reaction step
• C08G 18/44 - Polycarbonates
• C08G 18/48 - Polyethers

Abstract

[OBJECT] [OBJECT] The purpose of this invention is to provide a muscle-increasing ingredient with excellent safety. [OBJECT] The purpose of this invention is to provide a muscle-increasing ingredient with excellent safety. [MEANS FOR SOLUTION] [OBJECT] The purpose of this invention is to provide a muscle-increasing ingredient with excellent safety. [MEANS FOR SOLUTION] The problem can be solved by a composition for increasing muscle, comprising β-alanine or a salt thereof as an active ingredient of the present invention of the present invention.

IPC Classes  ?

• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

Abstract

outLoadLoad) of the power supply circuit (120) to change and modulating the resonant frequency (f) of the oscillator.

IPC Classes  ?

• H02N 2/18 - Electric machines in general using piezoelectric effect, electrostriction or magnetostriction producing electrical output from mechanical input, e.g. generators

Abstract

This invention provides an interleukin-31 (IL-31) production inhibitor and a pharmaceutical composition comprising the inhibitor. The invention also provides a novel compound useful as an active ingredient for an IL-31 production inhibitor. These comprise a compound represented by the following formula (1) or a salt thereof as an active ingredient: This invention provides an interleukin-31 (IL-31) production inhibitor and a pharmaceutical composition comprising the inhibitor. The invention also provides a novel compound useful as an active ingredient for an IL-31 production inhibitor. These comprise a compound represented by the following formula (1) or a salt thereof as an active ingredient: wherein A is a —NH—N═C(R1)— group, a divalent N-containing 5-membered heterocyclic group, or a —NH—CO— group, wherein R1 is a hydrogen atom or a C1-4 alkyl group, B is the same or different and is a C1-6 alkyl group optionally having one hydroxyl group, a mono or di(C1-6 alkyl)amino group optionally having one hydroxyl group, a halogen atom, a halo C1-6 alkyl group, a C2-6 alkynylene group, or a carboxy group, wherein at least one C1-6 alkyl group in the mono or di(C1-6 alkyl)amino group is optionally attached to a carbon atom adjacent to a carbon atom in the phenyl group to which it is attached, to form a 5- to 6-membered ring, and n is an integer of 1 to 5.

IPC Classes  ?

• A61K 31/655 - Azo (—N=N—), diazo (=N2), azoxy (N—O—N or N(=O)—N), azido (—N3) or diazoamino (—N=N—N) compounds
• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61K 31/415 - 1,2-Diazoles
• A61K 31/4164 - 1,3-Diazoles
• A61K 31/4192 - 1,2,3-Triazoles
• A61K 31/421 - 1,3-Oxazoles, e.g. pemoline, trimethadione
• A61K 31/4245 - Oxadiazoles
• A61K 31/433 - Thiadiazoles
• A61P 17/04 - Antipruritics

Abstract

A plasmalogen production–promoting culture medium according to the present invention includes lactose as a carbon source and is to be used to culture lactic acid bacteria.

IPC Classes  ?

• C12P 9/00 - Preparation of organic compounds containing a metal or atom other than H, N, C, O, S, or halogen
• C12N 1/20 - BacteriaCulture media therefor
• C12P 7/6427 - Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone